Prediction of cardiovascular events, diabetic nephropathy, and mortality by albumin concentration in a spot urine sample in patients with type 2 diabetes
Journal of Diabetes and its Complications, 06/12/2012
Viana LV et al. – Random urinary albumin concentration (UAC) ≥14mg/l predicted cardiovascular events, diabetic nephropathy, and mortality just as well as albumin:creatinine ratio (ACR). UAC may be used to assess cardiovascular and renal risks in patients with type 2 diabetes.
In this cohort, urinary albumin (immunoturbidimetry) was measured as 24-h urinary albumin excretion (UAE) and, in a random spot urine, as UAC and albumin:creatinine ratio (ACR).
Primary outcomes were:
1) cardiovascular events,
2) DN defined as a composite outcome [macroalbuminuria and/or decreased glomerular filtration rate (GFR) <60ml/min/1.73m2],
A total of 199 type 2 diabetic patients, aged 59.9±9.9years, were followed for 6.1±2.7years.
UAC ≥14.4mg/l, as determined by ROC curve, predicted DN and prediction for this and other outcomes were compared with traditional microalbuminuria cutoffs for ACR and UAE.
The outcomes frequency was: cardiovascular events=26.4%, DN=31.7% (23.5% decreased GFR; 13.6% macroalbuminuria) and death=8.50%. In Cox analyses, UAC ≥14mg/l increased the risk (hazard ratio, HR) for cardiovascular events 3.25 times (95% CI 1.43–7.38; P=0.005), 4.30 for DN composite outcome (95% CI 2.22–8.32; P<0.001), and 5.51 for death (95% CI 1.16–26.22; P=0.032).
Corresponding HRs of ACR ≥30mg/g were: 2.89 (95% CI 1.29–6.45; P=0.009) for cardiovascular events, 4.67 (95% CI 2.34–9.34; P<0.001) for DN composite outcome and 5.07 (95% CI 1.01–24.88; P=0.049) for death.
HRs of UAE ≥30mg/24-h were: 2.20 (95% CI 2.08–2.49; P=0.030) for cardiovascular events, 6.76 (95% CI 3.32–13.77; P<0.001) for DN composite outcome, and 2.47 (95% CI 0.72–8.42; P=0.150) for death.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.